126 related articles for article (PubMed ID: 37327527)
1. Arterial events in cancer patients treated with apixaban for venous thrombosis.
Larsen TL; Svalastoga M; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2023 Aug; 228():128-133. PubMed ID: 37327527
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism.
Hannevik TL; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2020 Dec; 196():238-244. PubMed ID: 32919178
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
Mokadem ME; Hassan A; Algaby AZ
Vascular; 2021 Oct; 29(5):745-750. PubMed ID: 33153401
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D
JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.
Bohula EA; Berg DD; Lopes MS; Connors JM; Babar I; Barnett CF; Chaudhry SP; Chopra A; Ginete W; Ieong MH; Katz JN; Kim EY; Kuder JF; Mazza E; McLean D; Mosier JM; Moskowitz A; Murphy SA; O'Donoghue ML; Park JG; Prasad R; Ruff CT; Shahrour MN; Sinha SS; Wiviott SD; Van Diepen S; Zainea M; Baird-Zars V; Sabatine MS; Morrow DA;
Circulation; 2022 Nov; 146(18):1344-1356. PubMed ID: 36036760
[TBL] [Abstract][Full Text] [Related]
6. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
Houghton DE; Vlazny DT; Casanegra AI; Brunton N; Froehling DA; Meverden RA; Hodge DO; Peterson LG; McBane RD; Wysokinski WE
Mayo Clin Proc; 2021 Nov; 96(11):2793-2805. PubMed ID: 34425962
[TBL] [Abstract][Full Text] [Related]
7. Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
Kim YN; Kim JC; Chung YS; Park J; Lee YJ; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Gynecol Oncol; 2022 Apr; 165(1):75-81. PubMed ID: 35216810
[TBL] [Abstract][Full Text] [Related]
8. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry.
Riva N; Ageno W; Schulman S; Beyer-Westendorf J; Duce R; Malato A; Santoro R; Poli D; Verhamme P; Martinelli I; Kamphuisen P; Dentali F;
Lancet Haematol; 2016 Jun; 3(6):e267-75. PubMed ID: 27264036
[TBL] [Abstract][Full Text] [Related]
9. Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease.
VanderPluym C; Esteso P; Ankola A; Hellinger A; Ventresco C; Hawkins B; Kobayashi RL; Williams R; Cetatoiu MA; Gauvreau K; Esch JJ
J Thromb Haemost; 2023 Jun; 21(6):1601-1609. PubMed ID: 36921920
[TBL] [Abstract][Full Text] [Related]
10. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet agents for the treatment of deep venous thrombosis.
Flumignan CD; Nakano LC; Baptista-Silva JC; Flumignan RL
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012369. PubMed ID: 35876829
[TBL] [Abstract][Full Text] [Related]
12. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
; Buller H; Deitchman D; Prins M; Segers A
J Thromb Haemost; 2008 Aug; 6(8):1313-8. PubMed ID: 18541000
[TBL] [Abstract][Full Text] [Related]
14. Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma.
Thomas AA; Wright H; Chan K; Ross H; Prasad P; Goodwin A; Holmes CE
J Thromb Thrombolysis; 2022 Feb; 53(2):479-484. PubMed ID: 34347201
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
Weitz JI; Segers A; Raskob G; Roberts RS; Francis C; Lassen MR; Fuji T; Swaim RM; Lee M; Peters G; DiBattiste PM; Tesfaye F; Strony J
J Thromb Haemost; 2019 Dec; 17(12):2081-2088. PubMed ID: 31529590
[TBL] [Abstract][Full Text] [Related]
16. Role of anticoagulants in therapy and prevention of recurrent venous thromboembolism in patients with cancer: a meta-analysis of randomized trials with apixaban.
Mareev VY; Mareev YV
Kardiologiia; 2022 Mar; 62(3):4-15. PubMed ID: 35414354
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Dawwas GK; Brown J; Dietrich E; Park H
Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial.
Ladha D; Mallick R; Wang TF; Caiano L; Wells PS; Carrier M
Thromb Res; 2021 Jun; 202():151-154. PubMed ID: 33857789
[TBL] [Abstract][Full Text] [Related]
19. Apixaban for the treatment of cerebral venous thrombosis: A case series.
Rao SK; Ibrahim M; Hanni CM; Suchdev K; Parker D; Rajamani K; Mohamed W
J Neurol Sci; 2017 Oct; 381():318-320. PubMed ID: 28991706
[TBL] [Abstract][Full Text] [Related]
20. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
